These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29908121)

  • 1. Pathological manifestations of Farber disease in a new mouse model.
    Beckmann N; Kadow S; Schumacher F; Göthert JR; Kesper S; Draeger A; Schulz-Schaeffer WJ; Wang J; Becker JU; Kramer M; Kühn C; Kleuser B; Becker KA; Gulbins E; Carpinteiro A
    Biol Chem; 2018 Sep; 399(10):1183-1202. PubMed ID: 29908121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    Beckmann N; Becker KA; Kadow S; Schumacher F; Kramer M; Kühn C; Schulz-Schaeffer WJ; Edwards MJ; Kleuser B; Gulbins E; Carpinteiro A
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic ceramide accumulation leads to severe and varied pathological consequences.
    Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
    EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    Dworski S; Lu P; Khan A; Maranda B; Mitchell JJ; Parini R; Di Rocco M; Hugle B; Yoshimitsu M; Magnusson B; Makay B; Arslan N; Guelbert N; Ehlert K; Jarisch A; Gardner-Medwin J; Dagher R; Terreri MT; Lorenco CM; Barillas-Arias L; Tanpaiboon P; Solyom A; Norris JS; He X; Schuchman EH; Levade T; Medin JA
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):386-394. PubMed ID: 27915031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
    Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
    Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
    Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.
    Yu FPS; Dworski S; Medin JA
    Sci Rep; 2018 Jan; 8(1):1808. PubMed ID: 29379059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acid ceramidase deficiency: Farber disease and SMA-PME.
    Yu FPS; Amintas S; Levade T; Medin JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin inflammation and impaired adipogenesis in a mouse model of acid ceramidase deficiency.
    Rybova J; Kuchar L; Sikora J; McKillop WM; Medin JA
    J Inherit Metab Dis; 2022 Nov; 45(6):1175-1190. PubMed ID: 36083604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease.
    Cozma C; Iurașcu MI; Eichler S; Hovakimyan M; Brandau O; Zielke S; Böttcher T; Giese AK; Lukas J; Rolfs A
    Sci Rep; 2017 Jul; 7(1):6149. PubMed ID: 28733637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
    Schuchman EH
    Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell transplantation leads to biochemical and functional correction in two mouse models of acid ceramidase deficiency.
    Rybova J; Sundararajan T; Kuchar L; Dlugi TA; Ruzicka P; McKillop WM; Medin JA
    Mol Ther; 2024 Oct; 32(10):3402-3421. PubMed ID: 39108096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
    Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
    Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.
    Bayerle A; Marsching C; Rabionet M; Dworski S; Kamani MA; Chitraju C; Gluchowski NL; Gabriel KR; Herzer S; Jennemann R; Levade T; Medin JA; Sandhoff R
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158741. PubMed ID: 32474112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turnover of endogenous ceramide in cultured normal and Farber fibroblasts.
    van Echten-Deckert G; Klein A; Linke T; Heinemann T; Weisgerber J; Sandhoff K
    J Lipid Res; 1997 Dec; 38(12):2569-79. PubMed ID: 9458280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
    Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
    Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency.
    Yu FPS; Molino S; Sikora J; Rasmussen S; Rybova J; Tate E; Geurts AM; Turner PV; Mckillop WM; Medin JA
    Lab Invest; 2019 Oct; 99(10):1572-1592. PubMed ID: 31186526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
    Kleynerman A; Rybova J; Faber ML; McKillop WM; Levade T; Medin JA
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
    Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.
    Bedia C; Camacho L; Abad JL; Fabriàs G; Levade T
    J Lipid Res; 2010 Dec; 51(12):3542-7. PubMed ID: 20871013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.